Dosing has begun in a long-term extension study testing Satellos Bioscience’s experimental oral therapy SAT-3247 in men with ...

Columnist Betty Vertin doesn't often dwell on her caregiver grief, but sometimes she needs to embrace it and let it flow through her.

In a $12 billion deal, Novartis has agreed to acquire Avidity Biosciences, which is developing several treatments for ...

As columnist Robin Stemple's FSHD progresses, he worries about how his increased care needs will affect his family caregivers ...